Re: Staurenghi et al.: Efficacy and safety of ranibizumab 0.5 mg for the treatment of macular edema resulting from uncommon causes: twelve-month findings from PROMETHEUS (Ophthalmology. 2018;125:850-862)
- PMID: 31122368
- DOI: 10.1016/j.ophtha.2018.12.020
Re: Staurenghi et al.: Efficacy and safety of ranibizumab 0.5 mg for the treatment of macular edema resulting from uncommon causes: twelve-month findings from PROMETHEUS (Ophthalmology. 2018;125:850-862)
Comment in
-
Reply.Ophthalmology. 2019 Jun;126(6):e43-e44. doi: 10.1016/j.ophtha.2018.12.021. Ophthalmology. 2019. PMID: 31122367 No abstract available.
Comment on
-
Efficacy and Safety of Ranibizumab 0.5 mg for the Treatment of Macular Edema Resulting from Uncommon Causes: Twelve-Month Findings from PROMETHEUS.Ophthalmology. 2018 Jun;125(6):850-862. doi: 10.1016/j.ophtha.2017.12.002. Epub 2018 Jan 20. Ophthalmology. 2018. PMID: 29371007 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources